On 5th August 2025, Vigonvita Life Sciences Co., Ltd. (hereinafter referred to as ‘VIGONVITA’) held the official ceremony for the first batch shipment of Class 1 new drug, 昂伟达® Simenafil Hydrochloride Tablets, across the country. Company leaders and heads of relevant departments, along with leaders from the contract manufacturing organisation, witnessed this historic moment for VIGONVITA.
昂伟达® (Simenafil Hydrochloride Tablets) was approved for market by the National Medical Products Administration (NMPA) on 8th July for the treatment of erectile dysfunction (ED). As a high-potency, highly selective phosphodiesterase 5 (PDE5) inhibitor with a novel chemical structure, 昂伟达® demonstrates significant clinical efficacy, high safety, broad applicability, and diverse usage scenarios, positioning as a potential best-in-class drug and offering ED patients a new treatment option.
昂伟达® exhibits extreme inhibition effect of PDE5, with its clinically recommended starting dose significantly lower than that of currently marketed drugs with the same target. A Phase III clinical trial demonstrated that 昂伟达® exhibits significant clinical efficacy, with patients achieving normal erectile function scores after following the clinical protocol. 昂伟达® also demonstrates a notable safety advantage, with a lower incidence of adverse reactions compared to currently marketed drugs with the same target, and no reports of visual abnormalities, back pain, or muscle pain.
Dr. Tian Guanghui, Chairman and General Manager of VIGONVITA, says that all steps from project initiation to successful market of 昂伟达® would not have been possible without the strong support of all departments. The successful launch and nationwide first shipment of 昂伟达® are milestones in VIGONVITA ‘s new drug development process. VIGONVITA will use this as a new starting point, focusing on clinical needs and social value, to accelerate the launch of more high-quality products and provide patients with new and better treatment options.
Chu Hong, general manager of Suzhou Thery Pharmaceutical Co., Ltd., the contract manufacturing company, says that as a contract manufacturer, the company will continue to ensure the timeliness and high quality of drug production and supply for the benefit of society.